Page last updated: 2024-10-23

baclofen and Stroke

baclofen has been researched along with Stroke in 36 studies

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
"Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions."9.27Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( Abouihia, A; Berthuy, N; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Loven, M; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018)
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)."9.27Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018)
"In total, 30 stroke patients with persistent hiccups were randomly assigned to receive baclofen (n = 15) or a placebo (n = 15) in a double-blind, parallel-group trial."9.19Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. ( Xu, M; Zhang, C; Zhang, R; Zhang, S, 2014)
"To evaluate the impact of intrathecal baclofen (ITB) on function and quality of life (QOL) and to obtain efficacy and safety data in poststroke spastic hypertonia."9.12Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. ( Francisco, GE; Grissom, SP; Ivanhoe, CB; McGuire, JR; Subramanian, T, 2006)
"To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors."9.10Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. ( Boake, C; Francisco, GE, 2003)
"Intrathecal infusion of baclofen is capable of maintaining a reduction in the spastic hypertonia resulting from stroke."9.09Intrathecal baclofen for spastic hypertonia from stroke. ( Brunner, RC; Guin-Renfroe, S; Hadley, MN; Meythaler, JM, 2001)
"This chapter will review the application of intrathecal baclofen (ITB) in the management of post-stroke hypertonia, a major complication that results in deformity and discomfort, and limits mobility and performance of activities of daily living (ADL)."8.84Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions. ( Francisco, GE, 2007)
"Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments."8.83Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. ( Cavalier, S; Francisco, GE; Grissom, S; Schiess, MC; Wiggs, L; Yablon, SA, 2006)
"Objective To assess quantitatively the efficacy of oral baclofen for spasticity poststroke."7.88Effect of oral baclofen on spasticity poststroke: responders versus non-responders. ( Maeshima, S; Mizuno, S; Shigeru, S; Takeda, K, 2018)
"To assess the effects of intrathecal baclofen (ITB) therapy for the treatment of poststroke spastic hemiparesis on quality of life, functional independence, and upper, lower extremity (UE, LE) motor functions."7.77Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. ( Acosta, F; Fisher, S; Lucke, J; Oh, IJ; Schiess, MC; Simpson, RK; Stimming, EF, 2011)
"To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke."7.74[Efficacy of intrathecal baclofen in the treatment of spasticity in stroke]. ( Cantalloube, S; Lamotte, D, 2007)
"To determine whether leg muscle stiffness is measurably reduced after intrathecal baclofen (ITB) in subjects with spastic hemiplegia."7.72Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. ( Bouilland, S; Bussel, B; Rémy-Néris, O; Tiffreau, V, 2003)
"This study was undertaken to determine the efficacy of intrathecal baclofen therapy in patients who suffer spasticity after a stroke."7.71Intrathecal baclofen for spasticity caused by thrombotic stroke. ( Gwartz, BL, 2001)
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)."6.74Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009)
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported."6.44Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007)
"To study the electromiographic (EMG) parameters and to evaluate the therapeutic efficacy of a combination of central (baclofen, baclosan) and peripheral (incobotulotoxinA, xeomin) muscle relaxants in the treatment of post-stroke spasticity (PSS)."5.30[Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity]. ( Frunza, DN; Iskra, DA; Koshkarev, MA; Kovalenko, AP, 2019)
"Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions."5.27Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( Abouihia, A; Berthuy, N; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Loven, M; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018)
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)."5.27Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018)
"In total, 30 stroke patients with persistent hiccups were randomly assigned to receive baclofen (n = 15) or a placebo (n = 15) in a double-blind, parallel-group trial."5.19Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. ( Xu, M; Zhang, C; Zhang, R; Zhang, S, 2014)
"To evaluate the impact of intrathecal baclofen (ITB) on function and quality of life (QOL) and to obtain efficacy and safety data in poststroke spastic hypertonia."5.12Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. ( Francisco, GE; Grissom, SP; Ivanhoe, CB; McGuire, JR; Subramanian, T, 2006)
"To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors."5.10Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. ( Boake, C; Francisco, GE, 2003)
"Intrathecal infusion of baclofen is capable of maintaining a reduction in the spastic hypertonia resulting from stroke."5.09Intrathecal baclofen for spastic hypertonia from stroke. ( Brunner, RC; Guin-Renfroe, S; Hadley, MN; Meythaler, JM, 2001)
"This chapter will review the application of intrathecal baclofen (ITB) in the management of post-stroke hypertonia, a major complication that results in deformity and discomfort, and limits mobility and performance of activities of daily living (ADL)."4.84Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions. ( Francisco, GE, 2007)
"Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments."4.83Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. ( Cavalier, S; Francisco, GE; Grissom, S; Schiess, MC; Wiggs, L; Yablon, SA, 2006)
"Objective To assess quantitatively the efficacy of oral baclofen for spasticity poststroke."3.88Effect of oral baclofen on spasticity poststroke: responders versus non-responders. ( Maeshima, S; Mizuno, S; Shigeru, S; Takeda, K, 2018)
"To assess the effects of intrathecal baclofen (ITB) therapy for the treatment of poststroke spastic hemiparesis on quality of life, functional independence, and upper, lower extremity (UE, LE) motor functions."3.77Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. ( Acosta, F; Fisher, S; Lucke, J; Oh, IJ; Schiess, MC; Simpson, RK; Stimming, EF, 2011)
"To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke."3.74[Efficacy of intrathecal baclofen in the treatment of spasticity in stroke]. ( Cantalloube, S; Lamotte, D, 2007)
"To determine whether leg muscle stiffness is measurably reduced after intrathecal baclofen (ITB) in subjects with spastic hemiplegia."3.72Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. ( Bouilland, S; Bussel, B; Rémy-Néris, O; Tiffreau, V, 2003)
"This study was undertaken to determine the efficacy of intrathecal baclofen therapy in patients who suffer spasticity after a stroke."3.71Intrathecal baclofen for spasticity caused by thrombotic stroke. ( Gwartz, BL, 2001)
"Adults (N=28) with muscle hypertonia due to stroke, trauma, or anoxia."2.75Effect of intrathecal baclofen bolus injection on lower extremity joint range of motion during gait in patients with acquired brain injury. ( Chow, JW; Horn, TS; Lee, JE; Stokic, DS; Yablon, SA, 2010)
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)."2.74Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009)
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported."2.44Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007)
"TTC staining was used to detect cerebral infarction volume, and the brain water content of rats in each group was determined by wet and dry weight method."1.91[Effects of Governor Vessel electroacupuncture on chloridion homeostasis in the cortex of rats with limb spasm after cerebral ischemia-reperfusion]. ( Guo, J; Li, JW; Li, RQ; Mei, JJ; Wang, YY; Zhang, JY; Zhang, LH, 2023)
" A complex dosing pattern was used more frequently in those with stroke (36."1.46Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury. ( Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017)
"Significant differences in dosing were found between diagnoses and trended to differ by ambulatory status at the end of the study, and similar trends could be observed in achieving initial stable dose."1.43Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review. ( Clearfield, JS; McGuire, J; Nelson, ME; Rein, LE; Tarima, S, 2016)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (47.22)29.6817
2010's16 (44.44)24.3611
2020's3 (8.33)2.80

Authors

AuthorsStudies
Cinone, N1
Santoro, L1
Spina, S1
Facciorusso, S1
Battaglia, M1
Baricich, A1
Marcogiuseppe, P1
Santamato, A1
Wang, YY1
Li, RQ1
Li, JW1
Mei, JJ1
Zhang, LH1
Zhang, JY1
Guo, J1
Iskra, DA1
Kovalenko, AP1
Koshkarev, MA1
Frunza, DN1
Surathi, P1
Sher, J1
Obaydou, N1
Pergament, KM1
Creamer, M2
Cloud, G2
Kossmehl, P2
Yochelson, M2
Francisco, GE7
Ward, AB2
Wissel, J2
Zampolini, M2
Abouihia, A2
Berthuy, N1
Calabrese, A2
Loven, M1
Saltuari, L3
Mizuno, S1
Takeda, K1
Maeshima, S1
Shigeru, S1
Lipták, J1
Chow, JW2
Yablon, SA3
Stokic, DS2
Zhang, C1
Zhang, R1
Zhang, S2
Xu, M1
Rush, R1
Kumbhare, D1
Clearfield, JS1
Nelson, ME1
McGuire, J1
Rein, LE1
Tarima, S1
Niehaus, MT1
Elliott, NC1
Katz, KD1
Lindsay, C1
Kouzouna, A1
Simcox, C1
Pandyan, AD1
Maneyapanda, MB1
McCormick, ZL1
Marciniak, C1
Reger, C1
Agarwal, S1
Patel, T1
Shah, N1
Patel, BM1
Kofler, M1
Quirbach, E1
Schauer, R1
Singer, M1
Huang, YS1
Hsiao, MC1
Lee, M1
Huang, YC1
Lee, JD1
Horn, TS1
Lee, JE1
Schiess, MC2
Oh, IJ1
Stimming, EF1
Lucke, J1
Acosta, F1
Fisher, S1
Simpson, RK1
Turner, M1
Nguyen, HS1
Cohen-Gadol, AA1
Rémy-Néris, O1
Tiffreau, V1
Bouilland, S1
Bussel, B1
Boake, C2
Yelnik, AP1
Smith, J1
Hu, MM1
Ivanhoe, CB2
Choudhuri, I1
Sarvananthan, N1
Gottlob, I1
Wiggs, L1
Cavalier, S1
Grissom, S1
McGuire, JR1
Subramanian, T1
Grissom, SP1
Lamotte, D1
Cantalloube, S1
Deer, TR1
Raso, LJ1
Garten, TG1
Taira, T1
Hori, T1
Abramson, SI1
Holmes, AA1
Hagberg, CA1
Gwartz, BL1
Meythaler, JM1
Guin-Renfroe, S1
Brunner, RC1
Hadley, MN1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239]Phase 461 participants (Actual)Interventional2009-11-30Completed
Effects of Neuromuscular Electrical Stimulation on Walking Ability and Quality of Life in Individuals With Chronic Stroke[NCT04673045]40 participants (Anticipated)Interventional2021-02-02Recruiting
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]8 participants (Actual)Interventional2009-11-30Terminated (stopped due to PI left institution)
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS): A Randomized, Controlled, Multi-center, Prospective Study Evaluating Dose Reduction in ITB Patients.[NCT04530955]92 participants (Anticipated)Interventional2020-09-24Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6

Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6

Interventionseconds (Mean)
ITB Therapy4.86
Best Medical Treatment (BMT)-2.48

Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6

"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy-0.99
Best Medical Treatment (BMT)-0.43

Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6

"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy-0.66
Best Medical Treatment (BMT)-0.17

Change in Functional Independence Measure (FIM) Score From Baseline to Month 6

FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy2.68
Best Medical Treatment (BMT)-2.58

Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6

"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy0.26
Best Medical Treatment (BMT)0.05

Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6

"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
Utility ScoreVAS
Best Medical Treatment (BMT)0.014.40
ITB Therapy0.099.68

Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6

"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
Actual painLeast PainWorst Pain
Best Medical Treatment (BMT)0.000.24-0.04
ITB Therapy-1.17-1.61-1.35

Change in SF-12 (12-item Short Form) From Baseline to Month 6

The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
PCSMCS
Best Medical Treatment (BMT)-1.13-0.82
ITB Therapy3.131.05

Healthcare Resource Utilization

Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6

,
InterventionParticipants (Count of Participants)
Baseline : general practitionerBaseline : neurologistBaseline : nurse (hospital setting)Baseline : nurse (home care)Baseline : orthopedic surgeonBaseline : otherITB test:general practitionerITB test: neurologistITB test :otherSecond Assessment: general practitionerSecond Assessment: neurologistSecond Assessment: nurse (home care)Second Assessment: otherweek 6: general practitionerweek 6: nurse (hospital setting)week 6: othermonth 3: general practitionermonth 3: neurologistmonth 3: othermonth 6: general practitionermonth 6: neurologistmonth 6: other
Best Medical Treatment (BMT)8801013NANANA5114NANANA8397211
ITB Therapy14410310113NANANANA422716838

Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance

Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6

InterventionParticipants (Count of Participants)
Baseline72364475Baseline72364476Month 372364475Month 372364476Month 672364475Month 672364476
HLPLLP
ITB Therapy22
Best Medical Treatment (BMT)24
ITB Therapy9
Best Medical Treatment (BMT)21
ITB Therapy6
ITB Therapy19
Best Medical Treatment (BMT)19
ITB Therapy5
Best Medical Treatment (BMT)5

Therapy Satisfaction

"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6

InterventionParticipants (Count of Participants)
Patient Satisfaction with Spasticity Reduction72364475Patient Satisfaction with Spasticity Reduction72364476Patient Therapy Reccomandation72364475Patient Therapy Reccomandation72364476
disagreeneutralagree
ITB Therapy2
Best Medical Treatment (BMT)7
ITB Therapy4
ITB Therapy16
Best Medical Treatment (BMT)11
Best Medical Treatment (BMT)5
ITB Therapy3
Best Medical Treatment (BMT)4
Best Medical Treatment (BMT)14

Reviews

5 reviews available for baclofen and Stroke

ArticleYear
Pharmacological interventions other than botulinum toxin for spasticity after stroke.
    The Cochrane database of systematic reviews, 2016, Oct-06, Volume: 10

    Topics: Baclofen; Botulinum Toxins, Type A; Clonidine; Diazepam; Humans; Muscle Relaxants, Central; Muscle S

2016
[Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
    Annales de readaptation et de medecine physique : revue scientifique de la Societe francaise de reeducation fonctionnelle de readaptation et de medecine physique, 2004, Volume: 47, Issue:8

    Topics: Arm; Baclofen; Botulinum Toxins, Type A; Clonidine; Combined Modality Therapy; Dantrolene; Ergonomic

2004
Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia.
    Topics in stroke rehabilitation, 2006,Fall, Volume: 13, Issue:4

    Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Practice Guideli

2006
Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions.
    Acta neurochirurgica. Supplement, 2007, Volume: 97, Issue:Pt 1

    Topics: Baclofen; Humans; Injections, Spinal; Muscle Hypertonia; Muscle Relaxants, Central; Stroke

2007
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state.
    Acta neurochirurgica. Supplement, 2007, Volume: 97, Issue:Pt 1

    Topics: Baclofen; Dystonia; Humans; Muscle Relaxants, Central; Pain; Persistent Vegetative State; Stroke

2007

Trials

10 trials available for baclofen and Stroke

ArticleYear
[Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2019, Volume: 119, Issue:12. Vyp. 2

    Topics: Baclofen; Botulinum Toxins, Type A; Humans; Muscle Relaxants, Central; Muscle Spasticity; Stroke; Tr

2019
Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS).
    Journal of neurology, neurosurgery, and psychiatry, 2018, Volume: 89, Issue:6

    Topics: Adult; Aged; Baclofen; Drug Administration Schedule; Female; Humans; Injections, Spinal; Male; Middl

2018
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
    Stroke, 2018, Volume: 49, Issue:9

    Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi

2018
Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial.
    Trials, 2014, Jul-22, Volume: 15

    Topics: Adult; Aged; Baclofen; Double-Blind Method; Hiccup; Humans; Middle Aged; Outcome Assessment, Health

2014
Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 87

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Cerebral Palsy; Child; Child, Preschool; Femal

2017
Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
    Neurorehabilitation and neural repair, 2009, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Baclofen; Child; Dose-Response Relationship, Drug; Female; GABA Agonists; Gait Di

2009
Effect of intrathecal baclofen bolus injection on lower extremity joint range of motion during gait in patients with acquired brain injury.
    Archives of physical medicine and rehabilitation, 2010, Volume: 91, Issue:1

    Topics: Adult; Ankle Joint; Baclofen; Brain Injuries; Female; Gait; Hip Joint; Humans; Injections, Spinal; J

2010
Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study.
    Archives of physical medicine and rehabilitation, 2003, Volume: 84, Issue:8

    Topics: Adult; Aged; Baclofen; Female; Hemiplegia; Humans; Infusion Pumps, Implantable; Injections, Spinal;

2003
Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life.
    Archives of physical medicine and rehabilitation, 2006, Volume: 87, Issue:11

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Baclofen; Female; Humans; Infusion Pumps

2006
Intrathecal baclofen for spastic hypertonia from stroke.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Cross-Over Studies; Dose-Response Relationship

2001

Other Studies

21 other studies available for baclofen and Stroke

ArticleYear
Reasons and Determinants of BoNT-A Treatment Discontinuation in Patients Living with Spasticity: A 10-Year Retrospective Analysis.
    Toxins, 2022, 09-29, Volume: 14, Issue:10

    Topics: Baclofen; Botulinum Toxins, Type A; Brain Injuries, Traumatic; Humans; Middle Aged; Multiple Scleros

2022
[Effects of Governor Vessel electroacupuncture on chloridion homeostasis in the cortex of rats with limb spasm after cerebral ischemia-reperfusion].
    Zhen ci yan jiu = Acupuncture research, 2023, Sep-25, Volume: 48, Issue:9

    Topics: Animals; Baclofen; Cerebral Cortex; Cerebral Infarction; Electroacupuncture; gamma-Aminobutyric Acid

2023
Sepsis or sympathetics? Paroxysmal sympathetic hyperactivity after pontine stroke.
    BMJ case reports, 2021, Jul-22, Volume: 14, Issue:7

    Topics: Autonomic Nervous System Diseases; Baclofen; Humans; Male; Middle Aged; Pons; Sepsis; Stroke

2021
Effect of oral baclofen on spasticity poststroke: responders versus non-responders.
    Topics in stroke rehabilitation, 2018, Volume: 25, Issue:6

    Topics: Administration, Oral; Adult; Aged; Ankle Joint; Baclofen; Electromyography; Female; Humans; Male; Mi

2018
[Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
    Ideggyogyaszati szemle, 2013, Nov-30, Volume: 66, Issue:11-12

    Topics: Aged; Baclofen; Clonidine; Comparative Effectiveness Research; Dantrolene; Female; Humans; Male; Mus

2013
Effect of intrathecal baclofen bolus injection on ankle muscle activation during gait in patients with acquired brain injury.
    Neurorehabilitation and neural repair, 2015, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Ankle; Baclofen; Biomechanical Phenomena; Brain Injuries; Electromyography; Femal

2015
Spasticity.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015, Apr-07, Volume: 187, Issue:6

    Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Humans; Multiple Sclerosis; Muscle Relaxants, Central; M

2015
Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review.
    Neuromodulation : journal of the International Neuromodulation Society, 2016, Volume: 19, Issue:6

    Topics: Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Dose-Response Relationship, Drug; Female; Hum

2016
Baclofen Toxicity Causing Acute, Reversible Dyskinesia.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2016, Volume: 12, Issue:4

    Topics: Aged, 80 and over; Back Pain; Baclofen; Coronary Artery Disease; Diabetes Mellitus; Drug Interaction

2016
Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
    PM & R : the journal of injury, function, and rehabilitation, 2017, Volume: 9, Issue:6

    Topics: Academic Medical Centers; Adult; Ambulatory Care; Baclofen; Brain Injuries, Traumatic; Cohort Studie

2017
Baclofen successfully abolished prolonged central hyperthermia in a patient with basilar artery occlusion.
    Acta neurologica Taiwanica, 2009, Volume: 18, Issue:2

    Topics: Aged; Baclofen; Body Temperature Regulation; Brain Stem; Female; Fever; Humans; Stroke; Vertebrobasi

2009
Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement.
    Neuromodulation : journal of the International Neuromodulation Society, 2011, Volume: 14, Issue:1

    Topics: Activities of Daily Living; Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Lower Extremi

2011
Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations.
    Journal of neurosurgery. Pediatrics, 2012, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Dystonic

2012
Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait.
    Archives of physical medicine and rehabilitation, 2003, Volume: 84, Issue:5

    Topics: Adult; Ankle; Baclofen; Biomechanical Phenomena; Body Weight; Brain Injuries; Cerebral Palsy; Electr

2003
Pharmacological risks following stroke.
    Physical therapy, 2005, Volume: 85, Issue:1

    Topics: Animals; Baclofen; Benzodiazepines; Humans; Muscle Relaxants, Central; Muscle Spasticity; Stroke

2005
Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury.
    Brain injury, 2005, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Aged; Baclofen; Brain Injuries; Child; Disability Evaluation; Drug Delivery Syste

2005
Survey of management of acquired nystagmus in the United Kingdom.
    Eye (London, England), 2007, Volume: 21, Issue:9

    Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists;

2007
[Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
    Annales de readaptation et de medecine physique : revue scientifique de la Societe francaise de reeducation fonctionnelle de readaptation et de medecine physique, 2007, Volume: 50, Issue:3

    Topics: Baclofen; Hemiplegia; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; Mu

2007
Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication.
    Pain medicine (Malden, Mass.), 2007, Volume: 8, Issue:3

    Topics: Adult; Aged; Baclofen; Catheterization; Female; Granuloma; Humans; Inflammation; Infusion Pumps, Imp

2007
Awake insertion of the Bonfils Retromolar Intubation Fiberscope in five patients with anticipated difficult airways.
    Anesthesia and analgesia, 2008, Volume: 106, Issue:4

    Topics: Accidents, Traffic; Adult; Aged; Baclofen; Body Size; Cervical Vertebrae; Equipment Design; Fiber Op

2008
Intrathecal baclofen for spasticity caused by thrombotic stroke.
    American journal of physical medicine & rehabilitation, 2001, Volume: 80, Issue:5

    Topics: Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Muscle Relax

2001